drugset / Trial / NCT00643097

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00643097 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with newly diagnosed glioblastoma multiforme.

Timeline

Start
2007-09
Primary completion
2012-01
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PEP-3 Vaccine — Intravitreal
Subject Temozolomide Small molecule 100 mg/m2 —
Subject Temozolomide Small molecule 200 mg/m2 —
Background sargramostim Protein / enzyme biologic — Intravitreal

Indications